Buy Luvesilocin Cas 2756001-39-3

Buy Luvesilocin Cas 2756001-39-3

Luvesilocin, also known as RE104 and FT-104, as well as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families which is under development for the treatment of psychiatric disorders.^[3][4] It is taken orally or by subcutaneous injection.^[3][2]

The drug is a prodrug ester of 4-HO-DiPT, which acts as a non-selective serotonin receptor agonist including of the serotonin 5-HT_2A receptor.^[5][6]

Luvesilocin was first described in the literature in 2021.^[5][7] It is under development for the treatment of postpartum depression and treatment-resistant depression.^{[8][9][10][11]} As of September 2025, the drug has reached phase 2 clinical trials.^[12] A phase 3 trial is planned for 2026.^[12]

The effects of luvesilocin have been clinically studied.^[2] It was evaluated at doses of 5 to 40 mg (equivalent to ~4–32 mg 4-HO-DiPT) by subcutaneous injection in this study.^[2] The drug was specifically assessed in terms of modified Drug Effects Questionnaire (DEQ) ratings, Mystical Experience Questionnaire (MEQ) ratings, and adverse effects.^[2] The mean duration of the psychedelic experience after administration of luvesilocin at a dose of 30 mg was found to be 3.6 hours.^[2][1]

Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT.^[13][14] This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A receptor.^[5][6] Activation of the serotonin 5-HT_2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics.^{[citation needed]}

4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.^[15] In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin (4-HO-DMT).^[16]

The drug activates basolateral amygdala (BLA) interneurons via the serotonin 5-HT_2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear (fear extinction) in rodents.^[5][6]

Given by subcutaneous injection, the elimination half-life of luvesilocin is 0.43 to 0.64 hours and of 4-HO-DiPT is 2.7 to 4.1 hours.^[2] The mean duration with this route at the employed dose was 3.6 hours.^[2]

The chemical synthesis of luvesilocin has been described.^[13]

Analogues of luvesilocin include 4-HO-DiPT (iprocin), 4-AcO-DiPT (ipracetin), 4-PrO-DiPT, 4-AcO-DMT (psilacetin), 4-PrO-DMT, and 4-GO-DMT (RE-109), among others.

Luvesilocin was first described in the literature in 2021.^[5][7]

Luvesilocin is the generic name of the drug and its INNTooltip International Nonproprietary Name.^[17] It is also known by its developmental code names RE104 or RE-104 and FT104 or FT-104.^[3]

Luvesilocin is not a controlled substance in Canada as of 2025.^[18]

Luvesilocin is not an explicitly controlled substance in the United States.^[19] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders.^{[3][1][20][21]} As of September 2025, it has reached phase 2 clinical trials for these indications.^[12] A phase 3 trial is planned for 2026.^[12] The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).^[3]